Skip to main content

(stockholm, December 8, 2021) Inhalation Research Services (IRS), the contract research organization of Inhalation Sciences Sweden AB (ISAB), received an order worth 55 752 euros for a new research project of an Italian pharmaceutical company Chiesi. The joint research project is between Chiesi and the Institute of Environmental Medicine (IMM) to Karolinska Institute (KI). Chiesi and IMM, leading research organizations in the field of inhalation, are back among ISAB’s customers.

the IRS the study is valued at 55 752 euros. It will be carried out at IMM’s research facilities at the Karolinska Institute in stockholm under the direction of the KI teacher Lena Palmberga long-time contributor to ISAB.

The study will use XposeALI®ISAB’s highly innovative solution in vitro cell culture tool that combines the aerosol capability of PreciseInhale® with cell exposures at an air-liquid interface that closely mimic physiological processes as they occur in the lungs.

2021 saw significant events around XposeALI®: in October, he was chosen to test a Mars dust substitute for the European Space Agency in another IMM research project. The same month, his US patent was extended. In November, the module received its US trademark, along with PreciseInhale, ISAB’s basic aerosol generation system.® and Dissolv in vitro dissolution moduleThis®.

CEO Manoush Masarrat: “Both Chiesi and KI are recognized worldwide as leading organizations in inhalation research. It’s a powerful endorsement of our technology that they choose us time and time again to get their first results. We’re also thrilled to see them recognizing Xpose’s unique capabilities and benefits.ALI®. We believe he will become a recognized leader in his niche.”

For more information on Inhalation Science, please contact:

Manoush Masarrat, CEO

Email: [email protected]

Mobile: +46 (0)73 628 9153

On Inhalation Sciences Sweden AB (publication)

Inhalation Sciences Sweden AB (publ) develops and markets state-of-the-art instruments and services for inhalation research. The company’s patented lab instruments, PreciseInhale® and DissolvIt®, enable researchers in the pharmaceutical industry to make drug pipeline decisions at an early stage, saving R&D departments time and resources, and allows researchers at academic institutions to define the impact of aerosols and small particles on our lungs. , and therefore our health, when inhaled.

The above information was provided by Inhalation Sciences Sweden AB in accordance with European market abuse regulations. The information has been provided, through the above contact person, for publication on December 8, 2021.,c3467906

(c) Decision 2021. All rights reserved., sources Press Releases – English